CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 6 (2025) Vis Cancer Med, 6 (2025) 8 References
Open Access
Issue
Vis Cancer Med
Volume 6, 2025
Article Number 8
Number of page(s) 6
DOI https://doi.org/10.1051/vcm/2025008
Published online 11 June 2025
  1. André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431. [Google Scholar]
  2. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044–1052. [CrossRef] [PubMed] [Google Scholar]
  3. Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, et al. Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019;37(26):2360–2367. [Google Scholar]
  4. Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516–3524. [Google Scholar]
  5. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer (Amsterdam, Netherlands). 2006;52(2):155–163. [Google Scholar]
  6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. [CrossRef] [PubMed] [Google Scholar]
  7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009;361(10):947–957. [Google Scholar]
  8. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New Engl J Med. 2018;378(2):113–125. [Google Scholar]
  9. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266. [Google Scholar]
  10. Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. New Engl J Med. 2023;389(21):1935–1948. [Google Scholar]
  11. Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23(1);108. [Google Scholar]
  12. Brenner BG, Friedman G, Margolese RG. The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer. Cancer. 1985;56(7):1543–1548. [CrossRef] [PubMed] [Google Scholar]
  13. Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2(3);271–279. [CrossRef] [PubMed] [Google Scholar]
  14. Wertel I, Polak G, Barczyński B, Kotarski J. Subpopulations of peripheral blood dendritic cells during chemotherapy of ovarian cancer. Ginekol Pol. 2007;78(10):768–771. [PubMed] [Google Scholar]
  15. Chen HH, Liang GK, Yao ZT, Zhang JQ, Chen X, Ding L. Advances in study of macrophages in chemotherapy resistance of cancer. Acta Pharm Sin. 2016;51(10):1513–1519. [Google Scholar]
  16. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 2000;47(5):632–637. [CrossRef] [PubMed] [Google Scholar]
  17. Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830. [CrossRef] [PubMed] [Google Scholar]
  18. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. [CrossRef] [PubMed] [Google Scholar]
  19. Liang H, Liu Z, Cai X, Pan Z, Chen D, Li C, et al. PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: an indirect comparison. Int J Cancer. 2019;145(11):3011–3021. [Google Scholar]
  20. Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, et al. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: a meta-analysis of randomized control trials. Cancer. 2021;127(5);777–786. [CrossRef] [PubMed] [Google Scholar]
  21. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2);198–211. [Google Scholar]
  22. Zhang M, Zhang G, Niu Y, Zhang G, Ji Y, Yan X, et al. Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial. Nat Commun. 2024;15(1):1512. [Google Scholar]
  23. He Q, Li J, Yin W, Song Z, Zhang Z, Yi T, et al. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol Immunother. 2011;60(5);715–730. [CrossRef] [PubMed] [Google Scholar]
  24. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–6721. [CrossRef] [PubMed] [Google Scholar]
  25. Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, et al. Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC. J Thorac Oncol. 2019;14(12):2152–2163. [Google Scholar]
  26. Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, et al. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer (Amsterdam, Netherlands). 2023;178:191–197. [Google Scholar]
  27. Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30(9):2528–2539. [Google Scholar]
  28. Le Texier T. Debunking the Stanford prison experiment. Am Psychol. 2019;74(7):823–839. [CrossRef] [PubMed] [Google Scholar]
  29. Alsan M, Wanamaker M. Tuskegee and the health of black men. Quarterly J Econ. 2018;133(1):407–455. [Google Scholar]
  30. Li F, Wang H, Xiang Y, Li R, Li C, Zhong R, et al. Comparison of different maintenance regimens following first-line immunochemotherapy for advanced non-small cell lung cancer. Transl Lung Cancer Res. 2023;12(12):2381–2391. [Google Scholar]
  31. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223. [Google Scholar]
  32. Briere DM, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, et al.The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol Cancer Ther. 2021;20(6):975–985. [Google Scholar]
  33. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK Reactivation. Cancer Discovery. 2021;11(8):1913–1922. [CrossRef] [PubMed] [Google Scholar]
  34. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–1115. [Google Scholar]
  35. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation – positive advanced non-small cell lung cancer (CheckMate 370). J Thor Oncol. 2018;13(5):682–688. [Google Scholar]
  36. Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thor Oncol. 2021;16(4):643–652. [Google Scholar]
  37. Gao G, Ni J, Wang Y, Ren S, Liu Z, Chen G, et al. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. Transl Lung Cancer Res. 2022;11(6):964–974. [Google Scholar]
  38. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. New Engl J Med. 2019;381(21):2020–2031. [Google Scholar]
  39. Chen Z, Zhu F, Li C, Li J, Cheng B, Xiong S, et al. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report. Ann Transl Med. 2021;9(5):424. [CrossRef] [PubMed] [Google Scholar]
  40. Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282. [Google Scholar]
  41. Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14–179. Cancer. 2020;126(19):4353–4361. [CrossRef] [PubMed] [Google Scholar]
  42. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New Engl J Med. 2017;377(20):1919–1929. [Google Scholar]
  43. Gu C, Wang X, Wang K, Xie F, Chen L, Ji H, et al. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer. J Immunother Cancer. 2024;12(1);e008386. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.